Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-05-05 | Reverse | 1:14 |
| 2023-03-23 | Reverse | 1:4 |
| 2017-01-11 | Reverse | 1:15464 |
| 2016-07-27 | Reverse | 1:15464 |
| 2010-12-03 | Reverse | 1:4 |
| 2007-05-03 | Reverse | 1:300 |
Protagenic Therapeutics, Inc. is a New York-based biopharmaceutical company developing therapeutics like PT00114 to treat stress-related neuropsychiatric and mood disorders by modulating brain stress responses.

A clinical-stage synthetic peptide mimicking brain peptide TCAP, targeting stress-related disorders like PTSD, depression, and anxiety, and serving as the company's lead drug candidate.
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
INDP | $1.29 | COMPARE |
GTBP | $0.29 | COMPARE |
REVB | $1.09 | COMPARE |
ARTL | $0.69 | COMPARE |
SPRC | $6.70 | COMPARE |
SLXN | $0.39 | COMPARE |
PBM | $4.33 | COMPARE |
CARM | $0.00 | COMPARE |